Compare ARRY & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARRY | VIR |
|---|---|---|
| Founded | 1989 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.5B |
| IPO Year | 2020 | 2019 |
| Metric | ARRY | VIR |
|---|---|---|
| Price | $7.22 | $8.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 8 |
| Target Price | $10.24 | ★ $19.63 |
| AVG Volume (30 Days) | ★ 6.3M | 3.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.56 | 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,284,141,000.00 | $68,556,000.00 |
| Revenue This Year | $15.64 | N/A |
| Revenue Next Year | $7.95 | $1,049.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.22 | N/A |
| 52 Week Low | $3.76 | $4.16 |
| 52 Week High | $12.23 | $10.91 |
| Indicator | ARRY | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 45.05 |
| Support Level | $6.53 | $5.14 |
| Resistance Level | $8.10 | $10.29 |
| Average True Range (ATR) | 0.41 | 0.47 |
| MACD | 0.18 | -0.18 |
| Stochastic Oscillator | 50.74 | 3.20 |
Array Technologies Inc manufacturer of ground-mounting systems used in solar energy projects. The company's segments include: the Array legacy operating segment (Array Legacy Operations) and the STI Operations operating segment (STI Operations). It derives maximum revenue from the Array legacy operating segment. Its product is an integrated system of steel supports, electric motors, gearboxes, and electronic controllers referred to as a single-axis tracker that moves solar panels throughout the day to maintain an optimal orientation to the sun, which increases their energy production. Geographically, the company's operations are in the United States, Australia, Spain, Brazil, and the rest of the world, with the United States deriving the majority of the revenue.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.